Mercer Global Advisors Inc. ADV cut its stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 2.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,456 shares of the financial services provider’s stock after selling 402 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in iShares Biotechnology ETF were worth $1,847,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Future Financial Wealth Managment LLC purchased a new stake in shares of iShares Biotechnology ETF during the 1st quarter valued at $27,000. Bbjs Financial Advisors LLC acquired a new stake in iShares Biotechnology ETF during the second quarter worth about $31,000. Pacifica Partners Inc. lifted its stake in shares of iShares Biotechnology ETF by 118.2% in the 1st quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. YHB Investment Advisors Inc. purchased a new stake in shares of iShares Biotechnology ETF during the 1st quarter worth about $37,000. Finally, Mather Group LLC. acquired a new stake in iShares Biotechnology ETF during the 1st quarter worth approximately $57,000. 62.45% of the stock is currently owned by hedge funds and other institutional investors.
iShares Biotechnology ETF Stock Down 1.6 %
Shares of IBB stock opened at $145.58 on Tuesday. iShares Biotechnology ETF has a fifty-two week low of $111.83 and a fifty-two week high of $150.57. The firm’s 50 day moving average price is $145.81 and its two-hundred day moving average price is $138.68.
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- Why Are Stock Sectors Important to Successful Investing?
- The Average 401k Balance by Age Explained
- 3 Monster Growth Stocks to Buy Now
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.